• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用腹腔内肿瘤细胞注射法建立体内卵巢癌小鼠模型。

Establishment of In Vivo Ovarian Cancer Mouse Models Using Intraperitoneal Tumor Cell Injection.

机构信息

Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA.

Department of Obstetrics and Gynecology, Department of Physiology, Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.

出版信息

Methods Mol Biol. 2022;2424:247-254. doi: 10.1007/978-1-0716-1956-8_16.

DOI:10.1007/978-1-0716-1956-8_16
PMID:34918299
Abstract

Mouse models-xenograft models, syngeneic models (directly implanted or chemically or virally induced), and genetically engineered mice (including transgenic and knockout methods) are invaluable for preclinical studies of ovarian cancer as they recapitulate the structures and microenvironments of tumors, which in vitro studies are unable to accomplish.This chapter describes the methodology and approaches for generating various murine models currently employed in ovarian cancer research. It covers the implantation of cells from ovarian cancer cell lines into mice by intraperitoneal injection.

摘要

鼠模型-异种移植模型、同基因模型(直接植入或化学或病毒诱导)和基因工程小鼠(包括转基因和敲除方法)对于卵巢癌的临床前研究非常有价值,因为它们再现了肿瘤的结构和微环境,而体外研究无法实现这一点。本章描述了目前用于卵巢癌研究的各种鼠模型的生成方法和途径。它涵盖了通过腹腔注射将卵巢癌细胞系的细胞植入小鼠体内的过程。

相似文献

1
Establishment of In Vivo Ovarian Cancer Mouse Models Using Intraperitoneal Tumor Cell Injection.采用腹腔内肿瘤细胞注射法建立体内卵巢癌小鼠模型。
Methods Mol Biol. 2022;2424:247-254. doi: 10.1007/978-1-0716-1956-8_16.
2
Immunocompetent mouse model of ovarian cancer for in vivo imaging.用于体内成像的卵巢癌免疫活性小鼠模型。
Methods Mol Biol. 2013;1049:425-33. doi: 10.1007/978-1-62703-547-7_32.
3
An Orthotopic Mouse Model of Ovarian Cancer using Human Stroma to Promote Metastasis.利用人源基质促进转移的卵巢癌原位小鼠模型。
J Vis Exp. 2021 Mar 23(169). doi: 10.3791/62382.
4
An orthotopic model of serous ovarian cancer in immunocompetent mice for in vivo tumor imaging and monitoring of tumor immune responses.用于体内肿瘤成像和肿瘤免疫反应监测的免疫健全小鼠浆液性卵巢癌原位模型。
J Vis Exp. 2010 Nov 28(45):2146. doi: 10.3791/2146.
5
AAV-mediated expression of 3TSR inhibits tumor and metastatic lesion development and extends survival in a murine model of epithelial ovarian carcinoma.腺相关病毒介导的 3TSR 表达抑制上皮性卵巢癌小鼠模型中的肿瘤和转移灶的发展并延长生存时间。
Cancer Gene Ther. 2020 May;27(5):356-367. doi: 10.1038/s41417-019-0108-8. Epub 2019 Jun 4.
6
Mouse Xenograft Model for Intraperitoneal Administration of NK Cell Immunotherapy for Ovarian Cancer.用于卵巢癌腹腔内给予NK细胞免疫疗法的小鼠异种移植模型
Methods Mol Biol. 2016;1441:277-84. doi: 10.1007/978-1-4939-3684-7_23.
7
Xenograft Models of Ovarian Cancer for Therapy Evaluation.卵巢癌治疗评估的异种移植模型。
Methods Mol Biol. 2022;2424:275-293. doi: 10.1007/978-1-0716-1956-8_18.
8
Orthotopic, syngeneic mouse model to study the effects of epithelial-stromal interaction.用于研究上皮-基质相互作用影响的原位同基因小鼠模型。
Methods Mol Biol. 2013;1049:409-23. doi: 10.1007/978-1-62703-547-7_31.
9
Establishment of two ovarian cancer orthotopic xenograft mouse models for in vivo imaging: A comparative study.建立两种用于体内成像的卵巢癌原位异种移植小鼠模型:一项比较研究。
Int J Oncol. 2017 Oct;51(4):1199-1208. doi: 10.3892/ijo.2017.4115. Epub 2017 Sep 4.
10
Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics.建立用于新型疗法临床前评估的上皮性卵巢癌患者来源的肿瘤异种移植模型。
Clin Cancer Res. 2017 Mar 1;23(5):1263-1273. doi: 10.1158/1078-0432.CCR-16-1237. Epub 2016 Aug 29.

引用本文的文献

1
The role of Piezo1 mechanotransduction in high-grade serous ovarian cancer: Insights from an in vitro model of collective detachment.Piezo1 机械转导在高级别浆液性卵巢癌中的作用:体外群体脱离模型的研究进展。
Sci Adv. 2024 Apr 26;10(17):eadl4463. doi: 10.1126/sciadv.adl4463.
2
PHGDH Inhibitor CBR-5884 Inhibits Epithelial Ovarian Cancer Progression via ROS/Wnt/-Catenin Pathway and Plays a Synergistic Role with PARP Inhibitor Olaparib.PHGDH 抑制剂 CBR-5884 通过 ROS/Wnt/-Catenin 通路抑制卵巢上皮性癌细胞进展,并与 PARP 抑制剂奥拉帕利发挥协同作用。
Oxid Med Cell Longev. 2022 Sep 5;2022:9029544. doi: 10.1155/2022/9029544. eCollection 2022.

本文引用的文献

1
Ovarian cancer statistics, 2018.卵巢癌统计数据,2018 年。
CA Cancer J Clin. 2018 Jul;68(4):284-296. doi: 10.3322/caac.21456. Epub 2018 May 29.
2
The latest animal models of ovarian cancer for novel drug discovery.用于新型药物发现的最新卵巢癌动物模型。
Expert Opin Drug Discov. 2018 Mar;13(3):249-257. doi: 10.1080/17460441.2018.1426567. Epub 2018 Jan 17.
3
Epidemiology of ovarian cancer: a review.卵巢癌流行病学综述
Cancer Biol Med. 2017 Feb;14(1):9-32. doi: 10.20892/j.issn.2095-3941.2016.0084.
4
Recent technological advances in using mouse models to study ovarian cancer.利用小鼠模型研究卵巢癌的近期技术进展。
Front Oncol. 2014 Feb 13;4:26. doi: 10.3389/fonc.2014.00026. eCollection 2014.
5
Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment.卵巢癌铂敏感复发:肿瘤微环境的作用
Front Oncol. 2013 Sep 24;3:251. doi: 10.3389/fonc.2013.00251.
6
New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches.关于卵巢癌发病机制的新假说为未来的针对性方法奠定了基础。
Biomed Res Int. 2013;2013:852839. doi: 10.1155/2013/852839. Epub 2013 Aug 25.
7
Latest research and treatment of advanced-stage epithelial ovarian cancer.晚期上皮性卵巢癌的最新研究和治疗。
Nat Rev Clin Oncol. 2013 Apr;10(4):211-24. doi: 10.1038/nrclinonc.2013.5. Epub 2013 Feb 5.
8
Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer.Rb、p53 和 Brca1 或 Brca2 的改变协同诱导转移性浆液性上皮性卵巢癌。
Cancer Res. 2012 Aug 15;72(16):4141-53. doi: 10.1158/0008-5472.CAN-11-3834. Epub 2012 May 22.
9
Ovarian cancer mouse models: a summary of current models and their limitations.卵巢癌小鼠模型:当前模型及其局限性综述。
J Ovarian Res. 2009 Sep 28;2(1):12. doi: 10.1186/1757-2215-2-12.
10
Mouse xenograft models vs GEM models for human cancer therapeutics.用于人类癌症治疗的小鼠异种移植模型与基因工程小鼠模型对比
Dis Model Mech. 2008 Sep-Oct;1(2-3):78-82. doi: 10.1242/dmm.000976.